Secondary stroke prevention: A European perspective

Cerebrovascular Diseases

Volumn 9, Issue SUPPL. 3, 1999, Pages 29-36

  Devuyst, Gérald ^a   Paciaroni, Maurizio ^a   Bogousslavsky, Julien ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CONFERENCE PAPER; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0032815391     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047552     Document Type: Conference Paper

References (48)

1. Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994;50:272-298.
2. MacMahon S, Rodgers A: Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994;12(suppl 10):5-14.
3. Winslow E, Bohannon N, Brunton SA, Mayhew HE: Lifestyle modification: Weight control, exercise, and smoking cessation. Am J Med 1996;101(suppl 4A):25-33.
4. Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-794.
5. Wolf PA, Cobb JL, D'Agostino RB: Epidemiology of stroke; in Barnett HJM, Mohr JP, Stein BM (eds): Stroke: Pathophysiology, Diagnosis and Management, ed 2. New York, Churchill Livingstone, 1992, pp 3-27.
6. Crouse JR, Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157: 1305-1310.
7. Mack WJ, Selzer RH, Hodis HN, Erickson JK, Liu CR, Liu CH, Crawford DW, Blankenholn DH: One year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24:1779-1783.
8. Adams HP, Byington RP, Hoen H, Dempsey R, Furberg CD: Effect of cholesterol lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cercbrovasc Dis 1995;5:171-177.
9. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ: Stroke, statins and cholesterol: A meta-analysis of randomized, placebo-con-trolled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
10. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
11. Masuhr F, Bush M, Einhaupl KM: Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke 1998;29: 339-345.
12. Goyan JE: The 'trials' of a long-term clinical trial: The Ticlopidine Aspirin Stroke Study and the Canadian-American Ticlopidine Study. Control Clin Trials 1989;10(suppl 4):236-244.
13. Gent M: A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death; in Hass WK, Easton JD (eds): Ticlopidine, Platelets and Vascular Disease. New York, Springer, 1993, pp 99-116.
14. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ: Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side-effects. Chest 1995;108 (suppl):247-257.
15. Easton JD: Antiplatelet therapy in the prevention of stroke. Drugs 1991;42(suppl):39-50.
16. Bellavance A: Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Stroke 1993;24:1452-1457.
17. Harbison JM: Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 1992;23: 1723-1727.
18. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG: The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;ii:1215-1220.
19. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Tech M, Sicurella J, Turpie AGG, and CATS Group: The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Stroke 1988;19:1203-1210.
20. Hass WK, Easton DJ, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
21. Herbert JM, Tissinier A, Defreyn G, Maffrand JP: Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury in rabbits. Arterioscl Thromb 1993;13:1171-1179.
22. CAPRIE Steering Committee: A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996;348:1329-1339.
23. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
24. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
25. Mousa SA, Mu DX, Lucchesi BR: Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonists in dogs. Stroke 1997; 28:830-836.
26. Koudstaal PJ: Secondary prevention following stroke or transient ischemic attack in patients with nonrheumatic atrial fibrillation: Anticoagulant therapy versus control; in Warlow C, van Gijn J, Sandercock P (eds): The Cochrane Database of Systematic Reviews. Issue I. London, British Medical Journal Publishing, 1995
27. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997;349: 1569-1581.
28. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349:1641-1649.
29. European Carotid Surgery Trialist's Collaborative Group: MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-1243.
30. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-453.
31. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Benefit of carotid endarterectomy in patients with symptomatic, moderate or severe stenosis. N Engl J Med 1998;329:1415-1425.
32. Chassin MR: Appropriate use of carotid endarterectomy. N Engl J Med 1998;339:1468-1471.
33. Tu JV, Hannan EL, Anderson GM, et al: The fall and rise of carotid endarterectomy in the United States and Canada. N Engl J Med 1998; 339:1441-1447.
34. Benavente O, Moher D, Phan B: Carotid endarterectomy for asymptomatic carotid stenosis: A meta-analysis. BMJ 1998;317:1477-1480.
35. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (ACAS): Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-1428.
36. Young B, Moore WS, Robertson JT, Toole JF, Ernst CB, Cohen SN, Broderick JP, Dempsey RJ, Hosking JD, for the ACAS Investigators: An analysis of perioperative surgical mortality and morbidity in the Asymptomatic Carotid Atherosclerosis Study. Stroke 1996;27:2216-2224.
37. Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh RE, Dempsey RJ, Caplan LR, Kresowik TF, Matchar DB, Toole JF, Easton JD, Adams HP, Brass LM, Hobson RW II, Brott TG, Sternau L: Guidelines for carotid endarterectomy. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1998;29:554-562.
38. European Atrial Fibrillation Trial Study Group: Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet 1993;342: 1255-1262.
39. European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
40. Hart RG, Sherman DG, Easton JD, Cairns JA: Prevention of stroke in patients with nonvalvular atrial fibrillation. Views and reviews. Neurology 1998;51:674-681.
41. Hart RG, Albers GW, Koudstaal PJ: Cardioembolic stroke; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease. Malden/Mass, Blackwell Science, vol II, pp 1392-1429.
42. Diener HC, Forbes C, Riekkinin PJ, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. II. Efficacy and safety data. J Neurol Sci 1997;151:S13-S17.
43. Diener HC, Lowenthal A: Antiplatelet therapy to prevent stroke: Risk of brain hemorrhage and efficacy in atrial fibrillation (letter). J Neurol Sci 1997;153:112.
44. Morocutti C, Amabile G, Fattapposta F et al, for the SIFA (Studio Italiano Fibrillazione Atriale) Investigators: Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997;28:1015-1021.
45. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, van Melle G: Stroke recurrence in patients with patent foramen ovale: the Lausanne Study, Lausanne Stroke with Paradoxical Embolism Study Group. Neurology 1996; 46:1301-1305.
46. Mas JL, Zuber M: Recurrent cerebrovascular events in patients with foramen ovale, atrial septal aneurysm or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995;130:1083-1088.
47. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE: Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 1992;86: 1902-1908.
48. Nendaz MR, Sarasin FP, Junod AF, Bogousslavsky J: Preventing stroke recurrence in patients with patent foramen ovale: antihrombotic therapy, foramen closure, or therapeutic abstention? A decision analytic perspective. Am Heart J 1998;135:532-541.